Results 121 to 130 of about 65,998 (238)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma. [PDF]

Target Oncol
Andreikos DA, Argyropoulou I, Theocharopoulos C, Anastasopoulou A, Stefanou D, Lyrarakis G, Schadendorf D, Gogas H, Ziogas DC.   +8 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions. [PDF]

ESMO Gastrointest Oncol
André T, Lonardi S, Zaanan A, Cohen R, Taieb J.   +4 more
europepmc   +1 more source

Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB–IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial

Cancer Science, EarlyView.
Kaplan–Meier survival curves comparing two‐cycle versus three‐cycle neoadjuvant sintilimab plus chemotherapy. (A) Disease‐free survival (DFS). (B) Overall survival (OS). CI, confidence interval; HR, hazard ratio; NR, not reached. ABSTRACT The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non‐small cell lung cancer (NSCLC ...
Miner Shao, Jie Yao, Lufeng Zhao, Ling Zhu, Baizhou Li, Lili Li, Bangyi Zhou, Yixin Zhang, Huiying Liu, Xiaoke Chen, Zuqun Wu, Zexin Chen, Junqiang Fan, Fuming Qiu   +13 more
wiley   +1 more source

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study. [PDF]

Curr Oncol
Uccello M, Gee AL, Bennett JA, Hazell HL, Ruiz-Echarri Rueda M, Beresford MJ.   +5 more
europepmc   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, Masayuki Hashimoto, Shoji Kitamura, Makoto Motoishi, Yuji Suzumura, Satoru Sawai, Yataro Daigo, Jun Hanaoka   +9 more
wiley   +1 more source

Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers

Cancer Science, EarlyView.
Experimental BBN models link gut microbial metabolism and diet‐microbiome interactions to urothelial carcinogenesis, while circulating extracellular vesicle‐associated bacterial DNA signals may reflect tumor immune contexture and immune checkpoint inhibitor outcomes in urothelial and renal cell carcinoma.
Atsunari Kawashima, Kentaro Jingushi, Takuro Saito, Toshihiro Uemura, Akinaru Yamamoto, Nesrine Sassi, Hiromu Horitani, Shunsuke Inoguchi, Yuki Horibe, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Norio Nonomura   +12 more
wiley   +1 more source

Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II-III non-small cell lung cancer in Sri Lanka. [PDF]

BMJ Oncol
Joseph N, Kularatna S, Senanayake S.
europepmc   +1 more source

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

Cancer Science, EarlyView.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, Satoshi Nishiwaki, Ichiro Kinoshita, Tetsuhiro Yoshinami, Chigusa Morizane, Yusuke Sato, Toshio Kubo, Mamoru Ito, Hiroshi Nishihara, Toru Mukohara, Hidekazu Shirota, Ryo Ko, Taro Shibata, Manabu Muto, Noboru Yamamoto   +16 more
wiley   +1 more source